|Day Low/High||80.33 / 81.11|
|52 Wk Low/High||64.18 / 83.78|
Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.
AstraZeneca shares, meanwhile, were less-than-moved by the news.
Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.
The continuous glucose monitor maker is an excellent growth opportunity.
Here's why the pharmaceutical company is a solid addition to your portfolio.
Tom Price will now head the Department of Health and Human Services.
Interpublic and United Parcel raise dividends, and a recap of notable dates.
The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.
Jim Cramer compares Allergan's growth to other pharma stocks.
Service-dog Study Shows Benefits to Emotional Well-being for Owners
The pharma giant will lever up should a strategic deal opportunity come along, too.
It's day 12 in Trump's America and the shine of an outsider presidency has already worn off.
Deep political and civic division over recent executive actions from the White House continue to make market waves on Tuesday.
Two industries should largely be avoided under this administration: pharma and retail.
Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.
Uncertainty surrounding an immigration ban on a number of Muslim-majority countries continues to fuel volatility on markets on Tuesday.
Eli Lilly CEO David Ricks is joining a group of drug industry executives meeting with President Donald Trump on Tuesday.
U.S. stock futures point lower Tuesday on continued concerns over Donald Trump's travel ban.
You are going to have to defend your book, if you have not already.
Jaguar Animal Health, Inc. (NASDAQ: JAGX) and Elanco US Inc.
Anything that slows down or distracts from a pro-business agenda would clearly be a risk.
Buckle in for a busy week filled with bellwether earnings reports, monetary policy decisions, and closely scrutinized economic numbers.